RxDoctor Payments Data

Pamela King

Psychiatric/Mental Health · Fairport, NYNPI 1124052527

Payments from drug & device makers

$1,565in general payments, 2019–2025

Across 69 payments — averaging $22.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$623
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$537
  • Lundbeck LLC$134
  • Alkermes, Inc.$81
  • AbbVie$77
  • Luye Pharma (USA) Ltd.$54
  • plus $58 from 3 others

What the payments were for

  • Food & beverage$1,565100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,565 in reported general payments places this provider in the 75th percentile of 2,385 psychiatric/mental health providers in New York.

See all psychiatric/mental health providers in New York

Medicare billing

Part B allowed, 2024
$15,447
Medicare patients
47
Services billed
250

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl36$61,427
Invega SustennaPaliperidone Palmitate13$46,568
Abilify MaintenaAripiprazole11$31,935
TrintellixVortioxetine Hydrobromide39$25,886
RexultiBrexpiprazole15$19,655
Aripiprazole147$7,755
Lurasidone Hcl34$6,283
Bupropion XlBupropion Hcl218$4,646
Lamotrigine OdtLamotrigine14$4,273
Duloxetine Hcl101$3,469
Lamotrigine167$2,517
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine32$2,326
Trazodone Hcl231$2,268
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine33$2,237
Hydroxyzine Hcl79$2,229

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$77$61,42736 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$27$25,88639 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,385 psychiatric/mental health providers in New York.

Other psychiatric/mental health in Fairport

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →